Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
- Mol. Cancer, Dec 09 2023, 22 (1) 200 | https://doi.org/10.1186/s12943-023-01886-9